Iterum Therapeutics plc announced the FDA approval of its new drug ORLYNVAHTM in Q4 2024, marking a significant milestone as it is expected to be the first branded product for uncomplicated ...
DUBLIN and CHICAGO, Feb. 07, 2025 (GLOBE NEWSWIRE) -- Iterum Therapeutics plc (Nasdaq: ITRM), a company focused on delivering next generation oral and IV antibiotics to treat infections caused by ...
16:34 EST Iterum Therapeutics (ITRM) files $150M mixed securities shelf Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>> See ...
Iterum reported a net loss of $6.6 million for Q4 and $24.8 million for full-year 2024. On a non-GAAP basis, the net loss was $3.1 million for Q4 and $17.6 million for the year, showing a ...
DUBLIN and CHICAGO, Feb. 07, 2025 (GLOBE NEWSWIRE) -- Iterum Therapeutics plc (Nasdaq: ITRM), a company focused on delivering next generation oral and IV antibiotics to treat infections caused by ...
DUBLIN and CHICAGO, Feb. 07, 2025 (GLOBE NEWSWIRE) -- Iterum Therapeutics plc (Nasdaq: ITRM), a company focused on delivering next generation oral and IV antibiotics to treat infections caused by ...
Hello, everyone, and welcome to the Iterum Therapeutics PLC Fourth-Quarter and Full Year 2024 Financial Results. My name is Ezra, and I will be your coordinator today. (Operator Instructions ...
ITERUM THERAPEUTICS ($ITRM) posted quarterly earnings results on Friday, February 7th. The company reported earnings of -$0.12 per share, beating estimates of -$0.22 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback